2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - New Orleans Theatre A
Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Adverse Events, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence
PAPER

239 Chemotherapy exposure is associated with genome wide somatic events and ultra-high risk double-hit TP53 alterations that impact cancer specific survival in previously treated Waldenström's macroglobulinemia.

Nickolas Tsakmaklis, Alberto Guijosa, MD2, Andres Ramirez-Gamero, MD3, Amanda Kofides, MSc4, Abigail Peachey5, Xia Liu, MD6, Hao Sun, MD, PhD7, Maria Luisa Guerrera, MD8, Christopher Patterson, MBA, MPH9, Andrew Branagan, MD, PhD10, Shayna Sarosiek, MD11, Jorge J Castillo, MD12, Steven Treon, MD, PhD13, Zachary R Hunter, PhD14
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Massachusetts General Hospital, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Purpose: BTK-inhibitors, proteasome-inhibitors and chemoimmunotherapy (CT) are mainstays of treatment in Waldenström's macroglobulinemia (WM). However, the genomic impact of prior therapy on the malignant clone, and its impact on WM disease outcomes remain unknown. As such, we performed to our knowledge, the largest whole-exome (WES) and RNA sequencing effort in CD19-selected bone marrow lymphoplasmacytic cells from previously treated WM patients and evaluated the relationship between prior CT-exposure, genome-wide somatic damage, and TP53ALT within the malignant clone, as well as their impact on overall survival (OS) and cancer-specific survival (CSS).

Methods: We performed whole exome (WES) on CD19+ bone marrow lymphoplasmacytic cells and matched germline tissue for 247 WM patients previously treated with and without CT. To ensure adequate tumor content, we restricted analysis to 164 patients with a MYD88L265P variant allele frequency of >5% and performed tumor RNA sequencing in 137 patients.

Results: Prior CT-exposure was associated with more somatic variants (median 35.5 vs. 30; p=0.012), copy number alterations (CNAs; median 2 vs. 1; p=0.036), inclusive of TP53 alterations (TP53ALT) that included Chr17p deletions and TP53 mutations (TP53MUT p=0.088). Double-hit TP53ALT were greater in those exposed to both alkylators and nucleoside analogues (18.8%) versus either alone (6.1%) or none (3.7%) (p=0.069). The number of CT-exposures was associated with a stepwise increase in the number of somatic variants and CNAs, with patients treated with ≥2 CT-containing lines of therapy having an increased number of somatic variants (median 43.5 vs. 31; p=0.001) and CNAs (median 3 vs. 1; p=0.022) compared to those with single or non-CT exposures. RNA sequencing confirmed TP53MUT expression and lower gene expression in TP53ALT samples (p=0.01). Double-hit TP53ALT conferred inferior overall (adjHR 3.61; p=0.004) and cancer specific (adjHR 8.06; p<0.001) survival, while single-hit TP53ALT resembled TP53 wild-type outcomes. Chr8p deletions (adjHR 3.39; p=0.018) and Trisomy Chr18 (HR: 5.45; p=0.002) emerged as novel, adverse CSS markers that enriched among CT-exposed patients. By Boruta analysis, double-hit TP53ALT ranked as the leading predictor of CSS. Many somatic variants and CNAs which could impact subsequent treatments were also enriched among CT-exposed patients, including mutations in MS4A1 (11% vs. 0%; p=0.003), TRAF2, UBR4, and MUC17 (7.3% vs. 0%; p=0.028), and Chr7 trisomy (10.1% vs. 0%; p=0.007). Somatic variants in SPI1 and HMCN2 (26.3% vs. 1.4% for each; p<0.001), IGFN1, MUC17, and NF1 (15.8% vs. 2.1% for each; p=0.021), and CNAs including Chr8p deletions (33.3% vs. 5%; p<0.001), Chr6q deletions (77.8% vs. 38.8%; p=0.002), Trisomy Chr4 (22.2% vs. 5.8%; p=0.034), Monosomy ChrX (22.2% vs. 5.8%; p=0.035), and Chr8q amplifications (16.7% vs. 3.6%; p=0.049) were also enriched in TP53ALT samples.

Conclusions: Prior CT-exposure is associated with enhanced tumor genome wide somatic events, including TP53ALT as well as somatic variants and CNAs that can impact subsequent therapies. Double hit TP53ALT emerged as the leading determinant of CSS in previously treated WM. Our findings provide a comprehensive genomic basis for understanding risks associated with upfront CT-exposure and acquisition of TP53ALT.

Zachary R Hunter, PhD: No relevant conflicts of interest to declare.